by GlyTherix | May 19, 2020
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
by GlyTherix | Sep 19, 2019
GlyTherix is among 25 biotech companies presenting at the AusBiotech Invest & Partnering Session on Thursday 31 October at Melbourne Convention & Exhibition Centre. Brad Walsh will provide an update on Miltuximab, the company’s novel treatment for solid...
by GlyTherix | Sep 26, 2018
Demerger clears the path for therapeutic company capital raising Sydney, Australia, 25 September 2018: Minomic International Ltd is pleased to announce it received strong shareholder approval to approve the demerger of its therapeutic subsidiary, GlyTherix Ltd,...
by GlyTherix | Jul 26, 2018
Facebook Twitter Google+ LinkedIn No drug-related adverse effects found in patients Sydney, Australia, 24th July 2018: Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate,...
by GlyTherix | Jun 27, 2017
June 27, 2017: [Sydney] Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of Miltuximab®, a chimeric version of Minomic’s MIL-38 anti-Glypican-1 antibody conjugated to the radioactive...
